News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>M Stanley Trims 3SBIO (01530.HK) TP to $34, Rating Overweight
Morgan Stanley released a research report incorporating 3SBIO (01530.HK)'s 2025 results, and lowering its 2026-2028 revenue forecasts by 5%/ 7% / 6% each, due to reduced sales ...
Reset
Send
The window will close in 5 seconds
<Research>M Stanley Trims 3SBIO (01530.HK) TP to $34, Rating Overweight
Close
Recommend
11
Positive
15
Negative
6
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

Morgan Stanley released a research report incorporating 3SBIO (01530.HK)  +0.250 (+1.317%)    Short selling $46.39M; Ratio 15.903%   's 2025 results, and lowering its 2026-2028 revenue forecasts by 5%/ 7% / 6% each, due to reduced sales forecasts for 3SBIO's core commercialized product, TPIAO, and milestone payments, mainly affected by the depreciation of USD/ RMB.

The broker also dropped the product gross profit margin and adjusted the operating expense ratio based on the latest trends, and cut its EPS forecasts for the same period by 8.3%/ 14.5%/ 12.4%, respectively.

Therefore, Morgan Stanley trimmed its target price to $34 from $38, with rating at Overweight.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.